共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma:a multi-center propensity score matched analysis of real-world practice显示文摘Background:To compare the treatment effectiveness and safety among transarterial infusion chemotherapy(TAI)with FOLFOX regimen,transarterial chemoembolization(TACE),and sorafenib in patients with BCLC stage C hepatocellular carcinoma(HCC).Methods:The data of consecutive patients with BCLC stage C HCC treated with TAI,TACE,or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed.Propensity-score matched(PSM)analysis was pairwise performed to reduce selection bias.Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method,log-rank test,Cox regression models,andχ2 test.Results:The median overall survival(OS)in the matched TAI cohort was significantly longer than the sorafenib cohort(19.6 vs.7.5 months,P=0.009),and the TACE cohort(estimated 27.8 vs.6.6 months,P<0.001).The difference in median progression-free survival(PFS)between the matched TAI and sorafenib cohorts was not significant(5.8 vs.2.3 months,P=0.219).The median PFS in the matched TAI cohort was significantly longer than the TACE cohort(6.5 vs.2.8 months,P<0.001).The objective response rate(ORR)in the matched TAI cohort was significantly higher than the sorafenib cohort(36.4%vs.0.0%,P<0.001)and the TACE cohort(48.7%vs.4.7%,P<0.001).The incidences of adverse events(AEs)were similar among these three cohorts.Conclusions:TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC. | Shaohua Li Jie Mei Qiaoxuan Wang Feng Shi Hongyan Liu Ming Zhao Lianghe Lu Yihong Ling Zhixing Guo Yabing Guo Xiaoming Chen Ming Shi Wan Yee Lau Wei Wei Rongping Guo | 2021 | Hepatobiliary Surgery and Nutrition2021，10，5： | 2 |
| 2 | Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients显示文摘Background:Hepatocellular carcinoma(HCC)is a major health problem and a primary cause of cancer-related death worldwide.Although great advances have achieved recently by large-scale high-throughput analysis,the precise molecular mechanism underlying HCC progression remains to be clearly elucidated.We investigated the relationship between Tescalcin(TESC),a candidate oncogene,and clinicopathological features of HCC patients and explored the role of TECS in HCC development.Methods:To identify new genes involved in HCC development,we analyzed The Cancer Genome Atlas liver cancer database,and TESC was selected for further investigation.HCC tissue microarray analysis for TESC and its association with clinicopathological features were performed to investigate its clinical significance.TESC was knocked down by using short-hairpin RNAs.Cell proliferation was analyzed by WST-1 assay and cell counting.Cell apoptosis was tested by fluorescence-activated cell sorting.A subcutaneous xenograft tumor model in nude mice was established to determine the in vivo function of TESC.Affymetrix microarray was used to identify its molecular mechanism.Results:TESC was significantly increased in HCC tissues compared with the adjacent normal liver tissues.High expression of TESC was detected in 61 of 172 HCC patients by tissue microarray.Large tumor(>5 cm)and elevated total bilirubin were associated with high TESC expression(both P<0.050).In multivariate analysis,TESC was identified as an independent prognostic factor for short overall survival of HCC patients.TESC knockdown impaired HCC cell growth in vitro and in vivo.TESC knockdown significantly increased cell apoptosis in HCC cell lines.Furthermore,Affymetrix microarray analysis revealed that TESC knockdown inhibited tumor proliferation-related pathways while activated cell death-related pathways.Conclusion:TESC was identified as an independent prognostic factor for short overall survival of HCC patients,and was critical for HCC cell proliferation and survival. | Zhong-Guo Zhou Jin-Bin Chen Rong-Xin Zhang Ling Ye Jun-ChengWang Yang-Xun Pan Xiao-HuiWang Wen-Xuan Li Yao-Jun Zhang Li Xu Min-Shan Chen | 2020 | Cancer Communications2020，40，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员